-
I'm supporting
@ProstateUK's fight to make#abiraterone available pre-chemotherapy on the NHS. Join me & sign up now http://campaignwith.us/9RSviz -
Alliance A031201:
#abiraterone +#enzalutamide not better than#enzalutamide alonepic.twitter.com/Vg1xxknNFJ
-
Received this
#ABBA inspired poem from one of my patients, really made me smile#worksbestifyousingalong#prostatecancerhumour#abiraterone pic.twitter.com/fuKU4IoOvi
-
metastasis-directed therapy, represents a viable and cost-effective therapy for
#oligometastatic#Prostatecancer compared to upfront systemics#abiraterone + ADT or#ADT alone#GU19pic.twitter.com/PpLQOLSLHb
-
Excellent presentations Now Discussion in hormone naive#prostatecancer session
#SOGUGsimposio#abiraterone or#docetaxel we don't now which is betterpic.twitter.com/sW3AcHimJo
-
Great news that
#abiraterone has been approved in Scotland as a first-line treatment for men with advanced prostate#cancer. This drug will now benefit many more men with the disease than before! https://www.icr.ac.uk/news-archive/the-icr-responds-to-approval-of-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer-on-the-nhs-in-scotland … -
To the hundreds of you who worked on
#abiraterone COU-302: a reminder that this study changed SOC worldwide and has now been cited >1000 X .@umnmedschool honored this on a#wallofscholarship. Congratulations! Let’s do it again!@Molina7A EricSmall@UMNCancer@UCSFCancerpic.twitter.com/NNecxSpWqT
Prikaži ovu nit -
Article Online: Optimal
#sequencing of#enzalutamide and#abiraterone acetate plus#prednisone in metastatic castration-resistant#prostatecancer: a randomised, open-label, phase 2 crossover trialpic.twitter.com/upPvqYbzjm
Prikaži ovu nit -
Bayer has been forced to unblind a trial looking at the combination of radium 223 (Xofiga) and
#abiraterone (Zytiga) after an excess of deaths and fractures were noted in the combination group compared to the abiraterone group alone - http://trendsinmenshealth.com/news/radium-223-abiraterone-combo-safety-issues/ … -
Dr. Kim Chi phase II of cabazitaxel (CAB) vs
#abiraterone or#enzalutamide in poor-risk#mCRPC showed improved CBR with CAB and prolonged SD, trend to OS benefit with first-line CAB@ASCO@ASCOpost#ASCO19pic.twitter.com/B3ORrhTjls
-
Fascinating feature on
#CancerEvolution
in @WIRED by@rkhamsi - the piece focuses on@MoffittNews research but also touches on@AndreaSottoriva's work@ICR_London (and the ICR-discovered drug#abiraterone /#Zytiga). https://www.wired.com/story/cancer-treatment-darwin-evolution/ …#cancerresearch -
-
A standard dose of prednisone of 5 mg/day as recommended previously may be inadequate to achieve physiologic glucocorticoid replacement in some patients with
#prostatecancer while on#abiraterone treatment. Additionally 10 mg of prednisone may cause adverse effects (continues) https://twitter.com/RosaCorcoy/status/1164390414453018624 …Prikaži ovu nit -
Three positive studies discussed in detail by
@Prof_IanD of@MonashUni#GU19@ASCO M0 NmCRPC#Darolutamide over PBO#ARAMİS M1 HSPC#Abiraterone over PBO#LATITUDE#Enza +#ADT over PBO#ARCHESpic.twitter.com/jiyMngRSE3Ovo je potencijalno osjetljiv multimedijski sadržaj. Saznajte više
-
Dr. Morris: simply not that much more anticancer activity w/addition of
#enzalutamide to#abiraterone vs enza alone in@ALLIANCE_org phase III trial in#mCRPC. More AEs with combination#asco19@ASCOPostpic.twitter.com/yynR2CA17u
-
Dr Mukherji reviews data
#abiraterone in advanced castration-sensitive#prostatecancer#MEPCC@AUBMC_Official @apccc17 How select patients?pic.twitter.com/zX1g0ihodS
-
In head to head comparison
#enzalutamide w better PSA resp cw#abiraterone but no difference in PFS in#CRPC#ASCO17pic.twitter.com/VDDbA5XaCg
-
#Abiraterone is one of the ICR’s biggest success stories. Read its story of scientific innovation and commercial partnership https://buff.ly/2Axsqvu pic.twitter.com/UYq99krQdi
-
Big day today, our 20th Cork patient has been registered onto the Neoadjuvant Abiraterone Prostate Study- Well done team!
@cancertrials_ie@CancerTrialCork@Paulkellyie#abiraterone#prostatecancer#cancertrialspic.twitter.com/nIxSLiWBez -
“Patients with DRD had significantly...longer median PFS vs those with wild-type tumors...The mutual exclusivity between DRD and PTEN could further explain why patients with WT DNA repair had worse outcome with therapy.”
#Abiraterone@JCO_ASCOhttp://ascopubs.org/doi/full/10.1200/JCO.2017.75.7310 …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.